TVTXHealthcareMid-Cap

Travere Therapeutics, Inc. Insider Trading Activity

Every SEC Form 4 insider transaction reported for Travere Therapeutics, Inc. (TVTX), sourced directly from SEC EDGAR and updated as new filings are accepted.

Last updated:

Quick Answer

Are TVTX insiders buying or selling?

Travere Therapeutics, Inc. insiders reported 0 open-market buys ($0) and 257 sells ($61.6M) across 257 Form 4 filings — a net selling position of $61.6M.

Source: SEC EDGAR Form 4

Key Statistics (as of Jun 16, 2026)

Total Form 4 filings
257
SEC EDGAR
Insider filers
15
Insider buys (0)
$0
Insider sells (257)
$61.6M

Insider sentiment

Net selling

Net insider flow of $61.6M in net selling.

Recent TVTX insider transactions

DateInsiderRoleTypeSharesPriceValue
Jun 16, 2026Timothy CoughlinDirectorSale10.0K$50.07$500.7K
Jun 16, 2026Roy D. BaynesDirectorSale4.5K$50.00$225.0K
May 19, 2026Timothy CoughlinDirectorSale3.3K$43.49$141.3K
May 7, 2026Roy D. BaynesDirectorSale4.5K$46.65$209.9K
May 7, 2026Meckler Jeffrey ADirectorSale8.0K$45.00$360.0K
May 7, 2026William E. RoteChief Research OfficerSale2.8K$43.95$121.4K
May 7, 2026Elizabeth E ReedChief Legal Officer and GCSale24.3K$45.06$1.1M
May 7, 2026Jula InrigCHIEF MEDICAL OFFICERSale22.5K$45.15$1.0M
May 7, 2026Peter HeermaCHIEF COMMERCIAL OFFICERSale2.2K$46.65$101.4K
May 7, 2026Eric M DubeCHIEF EXECUTIVE OFFICERSale22.5K$43.95$988.9K
May 7, 2026Christopher R. ClineCHIEF FINANCIAL OFFICERSale2.5K$46.31$115.4K
May 4, 2026Roy D. BaynesDirectorSale9.8K$44.22$431.1K
Apr 23, 2026William E. RoteChief Research OfficerSale9.1K$39.09$355.7K
Apr 16, 2026LYONS GARY ADirectorSale8.0K$41.07$328.6K
Apr 16, 2026Roy D. BaynesDirectorSale32.8K$41.29$1.4M
Apr 16, 2026Sandra CalvinSVP, CHIEF ACCOUNTING OFFICERSale22.0K$41.07$902.6K
Apr 16, 2026Peter HeermaCHIEF COMMERCIAL OFFICERSale7.2K$41.93$302.5K
Apr 16, 2026Eric M DubeCHIEF EXECUTIVE OFFICERSale64.0K$41.09$2.6M
Apr 16, 2026Elizabeth E ReedChief Legal Officer and GCSale51.5K$41.29$2.1M
Apr 16, 2026Christopher R. ClineCHIEF FINANCIAL OFFICERSale8.3K$41.91$349.0K
Apr 16, 2026Jula InrigCHIEF MEDICAL OFFICERSale8.2K$42.01$345.9K
Apr 7, 2026Roy D. BaynesDirectorSale10.0K$33.00$330.0K
Apr 2, 2026Eric M DubeCHIEF EXECUTIVE OFFICERSale60.0K$30.93$1.9M
Apr 2, 2026Elizabeth E ReedChief Legal Officer and GCSale10.0K$30.00$300.0K
Mar 18, 2026Elizabeth E ReedChief Legal Officer and GCSale10.0K$28.09$280.9K

Showing the 25 most recent of 257 Form 4 filings for Travere Therapeutics, Inc..

Most active TVTX insiders

  • Elizabeth E Reed40 filings
  • William E. Rote35 filings
  • Eric M Dube30 filings
  • Steve Aselage25 filings
  • Peter Heerma24 filings

Ask anything about TVTX insider activity

Use Trabud's AI agent to query Travere Therapeutics, Inc.'s Form 4 history in plain English — "Show me TVTX CEO purchases this year" or compare it against any other ticker.

Open the AI agent

TVTX insider trading FAQ

Are Travere Therapeutics, Inc. insiders buying or selling?

Across 257 SEC Form 4 filings, Travere Therapeutics, Inc. (TVTX) insiders reported 0 open-market purchases totaling $0 and 257 sales totaling $61.6M. That is a net selling position of $61.6M.

How many insiders trade TVTX stock?

15 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Travere Therapeutics, Inc.. The most recent filing was accepted on Jun 16, 2026.

Where does Trabud get TVTX insider trading data?

All TVTX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.

Looking for another company? Browse all tracked companies.

Related Content